Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Waldman Louis S.	2. Issuer Name and Ticker or Trading Symbol IRADIMED CORP [ IRMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) Former Controller
(Last) (First) (Middle) C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR.	3. Date of Earliest Transaction (MM/DD/YYYY) 7/24/2020
(Street) WINTER SPRINGS, FL 32708 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	7/24/2020		M⁽¹⁾		5155	A	$0	40155	D
Common Stock	7/24/2020		F		1254 ⁽²⁾	D	$23.47	38901	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽³⁾	7/24/2020		M ⁽¹⁾			750	⁽⁴⁾	⁽⁴⁾	Common Stock	750	$0	0	D
Restricted Stock Units	⁽³⁾	7/24/2020		M ⁽¹⁾			1476	⁽⁴⁾	⁽⁴⁾	Common Stock	1476	$0	0	D
Restricted Stock Units	⁽³⁾	7/24/2020		M ⁽¹⁾			1181	⁽⁴⁾	⁽⁴⁾	Common Stock	1181	$0	0	D
Restricted Stock Units	⁽³⁾	7/24/2020		M ⁽¹⁾			1748	⁽⁴⁾	⁽⁴⁾	Common Stock	1748	$0	0	D

Explanation of Responses:
(1)	As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on December 14, 2016, December 4, 2017, December 7, 2018, and December 7, 2019. Pursuant to the reporting person's separation agreement with the Issuer (the "Separation Agreement"), upon his separation from the Issuer on July 24, 2020 (the "Retirement Date"), all of his unvested restricted stock units, amounting to 5,155 shares of common stock, accelerated and vested as of the Retirement Date as follows: (i) 750 unvested restricted stock units accelerated and vested from the December 14, 2016 grant; (ii) 1,476 unvested restricted stock units accelerated and vested from the December 4, 2017 grant; (iii) 1,181 unvested restricted stock units accelerated and vested from the December 7, 2018 grant; and (iv) 1,748 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs").
(2)	Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 5,155 restricted stock units.
(3)	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
(4)	All of the unvested RSUs were accelerated on the Retirement Date pursuant to the terms of the Separation Agreement.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Waldman Louis S. C/O IRADIMED CORPORATION 1025 WILLA SPRINGS DR. WINTER SPRINGS, FL 32708				Former Controller